مارکرهای تومور انسانی: زیست شناسی و کاربردهای بالینی. مجموعه مقالات سومین کنفرانس بین المللی لاکو آمینو دی ایسکیا، ناپل، ایتالیا، ۲۳-۲۶ آوریل ۱۹۸۶ ۲۰۱۹
Human Tumor Markers: Biology and Clinical Applications. Proceedings of the Third International Conference Lacco Ameno d’Ischia, Napoli, Italy, April 23–26, 1986 2019

1. PREFACE

2. CONTENTS

3. OPENING LECTURES

4. WHAT DOES "MARKER" MEAN?

5. BIOMARKERS AND COLORECTAL CANCER GENETICS: LYNCH SYNDROMES I AND II

6. THE HUMAN C-MXB PROTQ-ONCOGENE PRODUCT: IDENTIFICATION AND DETECTION IN IMMATURE LYMPHOID, ERYTHROID, AND MYELOID CELLS

7. MOLECULAR BIOLOGY OF TUMOR MARKERS

8. UPDATE ON PROTO-ONCOGENES AND HUMAN CANCER

9. REGULATION OF THE ADENYLATE CYCLASE ACTIVITY OF CRI4 YEAST MUTANTS BY GTP AND GDP

10. RESTRICTION FRAGMENT LENGTH POLYMORPHISMS (RFLPs) AS GENETIC TUMOR MARKERS

11. dbl: A NEW TRANSFORMING GENE ISOLATED FROM A HUMAN DIFFUSE B-CELL LYMPHOMA

12. DEREGULATED ONCOGENES AS MARKERS FOR MELANOMA FORMATION IN XIPHOPHORUS

13. GENE MODULATION BY TUMOR PROMOTERS

14. MOLECULAR ANALYSIS OF HTLV-III AND DEVELOPMENT OF DIAGNOTIC AND VACCINE REAGENTS FOR AIDS

15. Transforming properties of human cytomegalovirus

16. TUMOR ANTIGENS

17. GENOMIC MARKERS OF TUMORS

18. THE ENIGMA OF A HUMAN TUMOR MARKER: TPA REVISITED

19. THE ENIGMA OF A HUMAN TUMOR MARKER: TPA REVISITED

20. ALPHA-FETOPROTEIN: ITS DIAGNOSTIC SPECIFICITY AND THERAPEUTIC USE OF ITS ANTIBOBY

21. NUCLEOLAR ANTIGENS IN CANCER TISSUES

22. POSSIBLE RELATIONSHIP OF MOUSE MAMMARY TUMOR VIRUS (MMTV) TO HUMAN CYTOTROPHOBLAST

23. TUMOR ASSOCIATED ANTIGENS FOR INDICATION AND CONTROL OF THERAPY

24. TUMOR MARKERS IN THE PATIENT WITH LUNG CANCER

25. TPA AND CEA. 7 YEARS OF CLINICAL EXPERIENCE

26. BIOCHEMICAL MARKERS IN PANCREATIC CANCER DIAGNOSIS

27. FACTORS CONTRIBUTING TO SUPPRESSION OF TUMOUR-HOST RESPONSIVENESS

28. ALPHAFETOPROTEIN: THE EPITOME OF CANCER MARKERS

29. RESPONSES OF PATIENTS TO THEIR CARCINOMA-ASSOCIATED T AND Tn-SPECIFIC ANTIGENS

30. INTERMEDIATE FILAMENTS AND DESMOSOME-ASSOCIATED PROTEINS (DESMOPLAKINS) IN MORPHOLOGIC TUMOR DIAGNOSIS

31. IMMUNOCHEMICAL CANCER CHARACTERIZATION

32. CHROMOSOMES AS HUMAN TUMOR MARKERS

33. IMMUNODIAGNOSIS OF HUMAN CARCINOMAS USING MONOCLONAL ANTIBODIES

34. USE OF ANTI-HCG MONOCLONALS IN RIA AND IMMUNOHISTOCHEMISTRY

35. MONOCLONAL ANTIBODY DEFINED MARKERS OF HUMAN MELANOMA CELLS

36. A MOLECULAR ANALYSIS OF THE CARCINOEMBRYONIC ANTIGEN (CEA) BY MONOCLONAL ANTIBODIES

37. MHC STATUS OF PRIMARY HUMAN COLORECTAL CARCINOMA

38. ASSESSMENT OF TUMOR ASSOCIATED MONOCLONAL ANTIBODY IN IMMUNOTHERAPY IN SYNGENEIC MODEL

39. MODIFIED NUCLEOSIDES

40. PSEUDOURIDINE IN BIOLOGICAL FLUIDS OF TUMOR-BEARING PATIENTS

41. PSEUDOURIDINE EXCRETION IN EXPERIMENTAL NEOPLASIAS OF RETROVIRAL ORIGIN

42. HIGH RESOLUTION QUANTITATIVE RP-HPLC-UV OF NUCLEOSIDES IN RNAs, DNAs, AND mRNAs

43. ANALYSIS OF RIBONUCLEOSIDES IN HUMAN BODY FLUIDS AND THEIR POSSIBLE ROLE AS PATHOBIOCHEMICAL MARKERS

44. NUCLEOSIDE PROFILES BY HPLC-UV IN SERUM AND URINE OF CONTROLS AND CANCER PATIENTS

45. ABERRANT URINARY EXCRETION OF MODIFIED NUCLEOSIDES IN PATIENTS WITH VARIOUS MANIFESTATIONS OF INFECTION WITH HTLV-III/LAV

46. MANAGEMENT OF HUMAN LEUKEMIAS

47. ACTIVATION OF CELLULAR ONCOGENES FOLLOWING CHROMOSOMAL REARRANGEMENTS AS A POSSIBLE PATHOGENETIC MECHANISM IN HTLV-I POSITIVE AND NEGATIVE T-HELPER-PHENOTYPE CLL

48. THERAPEUTIC OPTIONS IN ACUTE LEUKEMIAS

49. CHARACTERIZATION OF HUMAN NON-T ACUTE LYMPHOBLASTIC LEUKAEMIA: RESULTS OF A MULTICENTRE STUDY

50. HUMAN INTERLEUKIN 1 (ILI) AND INTERLEUKIN 2 (IL2) CAN FUNCTION AS AUTOCRINE GROWTH FACTORS FOR SOME NEOPLASTIC HUMAN LYMPHOID CELLS

51. PATIENT SURVEILLANCE

52. LONG TERM FOLLOW-UP AND THERAPY MONITORING OF CANCER: IS THE SIMULTANEOUS DOSAGE OF CEA AND TPA USEFUL?

53. NEW STRATEGIES FOR FOLLOW UP OF BREAST CANCER PATIENTS USING CEA, TPA, CA 15-3 AND CA 50

54. SERUM LIPID SIALIC ACID (LASA) TEST IN DETECTION AND MONITORING OF MALIGNANCIES, PARANEOPLASTIC AND RHEUMATHOID SYNDROMES

55. CLINICAL EVALUATION OF NEW TUMOR-ASSOCIATED ANTIGENS

56. AN OVERVIEW OF RESULTS. FUTURE PERSPECTIVES OF RADIOIMMUNODETECTION

57. TUMOR IMAGING WITH RADIOLABELLED ANTIBODIES

58. RECEPTORS AND HORMONES

59. HORMONES IN LUNG CANCER

60. CLINICAL VALIDATION OF IMMUNORADIOMETRIC ASSAY FOR MEASURING SERUM THYROGLOBULIN IN ANTI-THYROGLOBULIN AUTOANTIBODY POSITIVE SERA IN PATIENTS WITH THYROID CANCER

61. ALTERATIONS OF MEMBRANE TSH-RECEPTOR IN THYROID TUMORS

62. BINDING OF THE ESTROGEN RECEPTOR TO DEFINED REGIONS OF THE ESTROGEN RESPONSIVE CHICKEN OVALBUMIN GENE AND CONSTRUCTION OF A CONSENSUS SEQUENCE FOR THE DNA SITE WHICH BINDS THE RECEPTOR

63. NEW DEVELOPMENTS IN TUMOR MARKERS AND RECEPTORS IN HEAD AND NECK TUfORS

64. REGULATION OF HORMONE BINDING OF 17β-ESTRADIOL RECEPTOR BY TYROSINE PHOSPHORYLATION AND PHOSPHOTYROSINE DEPHOSPHORYLATION OF THE RECEPTOR

65. ENZYMES AND ISOENZYMES

66. SELECTIVE PROTEIN PHOSPHORYLATION BY PROTEIN KINASE C IN CELL ACTIVATION

67. PROTEIN KINASE ACTIVITIES OF NORMAL AND TRANSFORMED LYMPHOCYTES

68. DEFICIENCY OF 5'-DEOXY-5'-METHYLTHIOADENOSINE PHOSPHORYLASE IN HUMAN LEUKEMIA: BIOCHEMICAL ASPECTS AND CLINICAL IMPLICATIONS

69. THE ROLE OF MULTIPLE FORMS OF ALKALINE PHOSPHATASE IN CANCER DETECTION AND MONITORING

70. GLUTATHIONE TRANSFERASE AS A TUMOR MARKER IN HUMAN BREAST CARCINOMA

71. CANCER-RELATED CHANGES IN CREATINE KINASE ISOENZYMES AND VARIANTS

72. CLINICAL SIGNIFICANCE OF A REARRANGED HEXOKINASE ISOZYMES EXPRESSION IN NEOPLASTIC PHENOTYPE: THE ASTROCYTOMA MODEL

73. ANTIOXYGENIC ENZYMES AS TUMOR MARKERS: A CRITICAL REASSESSMENT OF THE RESPECTIVE ROLES OF SUPEROXIDE DISMUTASE AND GLUTATHIONE PEROXIDASE

74. NOVEL ASPECTS OF THE HUMAN ALDOLASE GENE FAMILY AND ITS EXPRESSION IN TUMOR CELLS

75. AUTHOR INDEX

76. SUBJECT INDEX